Patent US4952607A successfully refreshed from Google Patents.
US4952607A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Copper complex for treating cancer
Assignee: International Copper Research Assn Inc
•
Filing: 1986-01-30
•
Granted: 1990-08-28
•
Expires: 2006-01-30
Abstract
Abstract The present invention relates to copper complexes exhibiting superoxide dismutase-like activity in mammalian cells. The copper complexes, which act as superoxide radical (O 2 - ) scavengers, are used in treating cancer by replacing the lost superoxide dismutase activity which characterizes tumor systems. The low molecular weight and lipid solubility of the copper complexes facilitate penetration of cell membranes. Depending upon the specific type of copper complex used, treatment may result in decreased tumor growth, increased survival of the host organism, decreased tumor metastasis or induced morphological differentiation of cancerous cells. The copper complexes used according to the invention include copper salicylate complexes, their solvates as well as mixtures thereof. A method for the treatment of cancer using these copper complexes is also disclosed.
Inventors
- 👤 John R. J. Sorenson
- 👤 Larry W. Oberley
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:04
CPC Classifications
C; C07; C07F; C07F1/00; C07F1/005
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
46 words
A method for treating cancer types in mammals, said cancer types being characterized by abnormal superoxide dismutase activity, comprising administration to a mammal having a tumor characterized by abnormal superoxide dismutase activity of a therapeutically effective amount of a copper salicylate complex and an anti-cancer drug.
Claim 2
Independent Claim
46 words
A method for treating cancer types in mammals, said cancer types being characterized by abnormal superoxide dismutase activity, comprising administration to a mammal having a tumor characterized by abnormal superoxide dismutase activity of a therapeutically effective amount of a copper salicylate complex and an anti-cancer drug.
Claim 3
Independent Claim
79 words
A method for treating cancer types in mammals, said cancer types being characterized by abnormal levels of superoxide dismutase activity, comprising administration to a mammal having a tumor characterized by abnormal superoxide dismutase activity of a therapeutically effective amount of (i) a copper salicylate complex selected from the group consisting of Cu(II)(salicylate) 2 , Cu(II)(3,5-diisopropylsalicylate) 2 , Cu(II)(3,5 ditertiarytbutylsalicylate) 2 , Cu(II) 2 (aspirinate) 4 (pyridine) 4 and CU(II) 2 (aspirinate) 4 (DMSO) 4 and (ii) an anti-cancer drug.
Claim 4
Independent Claim
79 words
A method for treating cancer types in mammals, said cancer types being characterized by abnormal levels of superoxide dismutase activity, comprising administration to a mammal having a tumor characterized by abnormal superoxide dismutase activity of a therapeutically effective amount of (i) a copper salicylate complex selected from the group consisting of Cu(II)(salicylate) 2 , Cu(II)(3,5-diisopropylsalicylate) 2 , Cu(II)(3,5 ditertiarytbutylsalicylate) 2 , Cu(II) 2 (aspirinate) 4 (pyridine) 4 and CU(II) 2 (aspirinate) 4 (DMSO) 4 and (ii) an anti-cancer drug.
Claim 5
Dependent Claim
13 words
The method according to claim 2, wherein the anti-cancer drug is bis-dichloroethyl-N-nitroso urea.
Claim 6
Independent Claim
44 words
A method for treating cancer types in mammals, said cancer types being characterized by abnormal superoxide dismutase activity, comprising administration to a mammal having a tumor characterized by abnormal superoxide dismutase activity of a therapeutically effective amount of Cu(II)(3,5 ditertiarybutylsalicylate) 2 and bis-dichloroethyl-N-nitroso urea.
Claim 7
Independent Claim
44 words
A method for treating cancer types in mammals, said cancer types being characterized by abnormal superoxide dismutase activity, comprising administration to a mammal having a tumor characterized by abnormal superoxide dismutase activity of a therapeutically effective amount of Cu(II)(3,5 ditertiarybutylsalicylate) 2 and bis-dichloroethyl-N-nitroso urea.
Claim 8
Dependent Claim
13 words
The method according to claim 2, wherein the cancer type is Ehrlich carcinoma.
Claim 9
Dependent Claim
13 words
The method according to claim 4, wherein the cancer type is Ehrlich carcinoma.
Claim 10
Dependent Claim
13 words
The method according to claim 2, in which the composition is administered intramuscularly.
Claim 11
Dependent Claim
13 words
The method according to claim 2, in which the composition is administered intravenously.
Claim 12
Dependent Claim
13 words
The method according to claim 2, in which the composition is administered subcutaneously.
Claim 13
Dependent Claim
13 words
The method according to claim 2, in which the composition is administered topically.
Claim 14
Dependent Claim
13 words
The method according to claim 2, in which the composition is administered orally.
Claim 15
Dependent Claim
13 words
The method according to claim 2, in which the composition is administered intraperitoneally.
Claim 16
Dependent Claim
13 words
The method according to claim 4, in which the composition is administered intramuscularly.
Claim 17
Dependent Claim
13 words
The method according to claim 4, in which the composition is administered intravenously.
Claim 18
Dependent Claim
13 words
The method according to claim 4, in which the composition is administered subcutaneously.
Claim 19
Dependent Claim
13 words
The method according to claim 4, in which the composition is administered topically.
Claim 20
Dependent Claim
13 words
The method according to claim 4, in which the composition is administered orally.
Claim 21
Dependent Claim
13 words
The method according to claim 4, in which the composition is administered intraperitoneally.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-08-27 | 1994-02-26 | 1994-08-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-08-27 | 1998-02-26 | 1998-08-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-08-27 | 2002-02-26 | 2002-08-28 | $7700.00 | Window Closed / Lapsed |